Effects of isomeric 2-(Arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells Christopher A. CarterKenneth W. Bair Preclinical Studies Pages: 125 - 136
Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065 Li H. LiRobert C. KellyThomas F. DeKoning Preclinical Studies Pages: 137 - 148
Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro De-Lin DuDonna A. VolpeMartin J. Murphy Jr. Preclinical Studies Pages: 149 - 157
Pharmacokinetics of 2′,3′-dideoxyadenosine in dogs M. Guillaume WientjesMichael E. PlackeJoseph E. Tomaszewski Preclinical Studies Pages: 159 - 168
A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to Adriamycin Catherine A. O'BrianNancy E. WardDominic Fan Preclinical Studies Pages: 169 - 179
Toxicity trials of amsacrine (AMSA) and etoposide +/− azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study C. Philip SteuberTate HolbrookJeffrey Krischer Clinical Studies Pages: 181 - 184
Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas John P. CrownSubhash GulatiJoseph Bertino Clinical Studies Pages: 185 - 186
Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer James R. RigasMark G. KrisLinda D. Marks Clinical Studies Pages: 187 - 190
Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy Jacob B. Green IIIStephanie GreenDarryl L. Wallace Clinical Studies Pages: 191 - 193
Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors Sarah A. TaylorJohn CrowleyJerry T. Guy Clinical Studies Pages: 195 - 197
Phase I studies of trimetrexate using single and weekly dose schedules Susan D. HuanSewa S. LeghaIrwin H. Krakoff Clinical Studies Pages: 199 - 206
A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus Robert E. SlaytonJohn A. BlessingBarrie Anderson Clinical Studies Pages: 207 - 208
Working conference on biomodulator and chemotherapy combination therapies Thomas D. BrownMalcolm S. MitchellGeoffrey R. Weiss Meeting Report Pages: 209 - 214